HBMN:SWX
HBM Healthcare Investments AG
CHF 223.50
0.00%
(0.00) 1D
Nov 12, 5:30:00 PM GMT+1 · CHF
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HBMN...
Open
CHF 224.00
High
CHF 225.00
Low
CHF 221.00
Mkt. cap
1.48B
Avg. vol.
5.87K
Volume
5.63K
Dividend
4.03%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
4.20
52-wk high
CHF 258.00
52-wk low
CHF 195.40
EPS
CHF 53.19
Shares outstanding
6.62M
Open
CHF 224.00
High
CHF 225.00
Low
CHF 221.00
Mkt. cap
1.48B
Avg. vol.
5.87K
Volume
5.63K
Dividend
4.03%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
4.20
52-wk high
CHF 258.00
52-wk low
CHF 195.40
EPS
CHF 53.19
Shares outstanding
6.62M
News stories
From web sources and news partners
Coinbase
·
3 minutes ago
About Ondo US 500 Capital Shielded Portfolio
Traders Union
·
54 minutes ago
Bitcoin underperforms gold and S&P over 5 years, Joe Consorti notes
Yahoo Finance
·
8 hours ago
The S&P 500 Is Hiding a Sneaky Risk. Here's How Investors Can Prepare for Potential Volatility.
BigGo Finance
·
15 hours ago
Micron and Sandisk Ride an AI Memory Crunch to the Top of the S&P 500
Profile
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
About HBM Healthcare Investments AG
CEO-
Employees-
FoundedJul 12, 2001
HeadquartersZug, Zug, Switzerland
SectorFinancials
IndustryCapital market
Websitehbmhealthcare.com